Margarita Romeo-Marin

Badalona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study.

Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 14, 2024

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 10, 2024

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.

Journal: ESMO open
Published: July 01, 2021

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: January 24, 2019

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Journal: International journal of molecular sciences
Published: September 29, 2018

Erratum to: Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor.

Erratum to: Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor.

Journal: World journal of surgical oncology
Published: August 10, 2016

Outcome prognostic factors in inoperable malignant bowel obstruction.

Outcome prognostic factors in inoperable malignant bowel obstruction.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: April 26, 2016

Gastrointestinal perforation induced by bevacizumab treatment in cervix carcinoma

Gastrointestinal perforation induced by bevacizumab treatment in cervix carcinoma

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
Published: December 01, 2015

Appendiceal mixed adenoneuroendocrine carcinomas, a rare entity that can present as a Krukenberg tumor: case report and review of the literature.

Appendiceal mixed adenoneuroendocrine carcinomas, a rare entity that can present as a Krukenberg tumor: case report and review of the literature.

Journal: World journal of surgical oncology
Published: July 08, 2015

Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor.

Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor.

Journal: World journal of surgical oncology
Published: June 11, 2012
Showing 1-10 of 10

Last Updated: 09/26/2026